No Data
cathay biotech inc. (688065.SH): The private placement application has been approved by the China Securities Regulatory Commission for registration.
Gelonghui December 3rd news | Cathay Biotech Inc. (688065.SH) announced that the company recently received the approval from the China Securities Regulatory Commission for the registration of issuing stocks to specific entities, as detailed in the document Permit No. [2024] 1662 issued by the regulatory authority. The content of the approval is as follows: 1. Approval for your company's registration application to issue stocks to specific entities. 2. Your company should strictly implement the issuance according to the submission of documents to the Shanghai Stock Exchange and the issuance plan. 3. This approval is valid for 12 months from the date of registration approval.
cathay biotech inc. (688065.SH): First-time repurchase of 0.0336 million shares.
Gelonghui, on November 27, announced that cathay biotech inc. (688065.SH) launched its first share buyback on November 27, 2024, using the centralized bidding method through the shanghai stock exchange trading system. A total of 33,607 shares were repurchased, accounting for 0.0058% of the company's total share capital of 583,378,039 shares. The highest transaction price was 45.30 yuan/share, the lowest price was 44.08 yuan/share, and the total funds paid amounted to 1,502,599.00 yuan (excluding stamp duty, transaction commissions, and other transaction costs).
Cathay Biotech Inc. (688065.SH): The developed biobased polyamide continuous fiber composite materials have started sample trial production and verification in the new energy, modern construction, transportation logistics, and other fields.
Gelonghui, November 21st. Cathay Biotech Inc. (688065.SH) stated on the investor interaction platform that currently, the company has started sample trial production and verification of the bio-based polyimide continuous fiber composite materials developed in the fields of new energy, modern construction, transportation logistics, etc. Based on the cost-effectiveness advantages and market potential of such bio-based new materials, the company has conducted business docking with multiple subsidiaries and joint ventures of China Merchants Group, several pilot projects are in progress.
Cathay Biotech Inc. (688065): Performance improvement in the third quarter, opening up application space for bio-based new materials.
Event overview: On October 30, 2024, the company released its third-quarter report for 2024. In the first three quarters of 2024, the company achieved a revenue of 2.215 billion yuan, +41.49% year-on-year; net income attributable to the parent company was 0.345 billion yuan, year-on-year.
Express News | A-Share private placement overview: 4 companies disclose private placement progress.
Express News | Cathay Biotech Inc.: Application for issuing A-shares to specific targets has been approved by the Shanghai Stock Exchange.
No Data
No Data